Study on CK20 mRNA and hTERT mRNA expression and tumor micrometastasis in peripheral blood in patients with colorectal carcinoma
AIM: To detect the expressions of cytokeratin 20 (CK20) mRNA and human telomerase reverse transcriptase (hTERT) mRNA in peripheral blood of patients with colorectal carcinoma and to discuss whether they can be used as molecular biological markers of predicting micrometustasis in peripheral blood and evaluating prognosis. METHODS: Peripheral blood of 32 colorectal carcinoma patients, 11 benign colorectal lesion patients and 20 healthy examination cases was detected by RT-PCB technique for qualitative and semi-quantitative analysis of CK20 mRNA and hTERT mRNA. Hnman SGC-7901 gastric adenocarcinoma cell lines were used as positive controls. The results were analyzed by SPSS13.0 software. RESULTS: The positive expression rate of CK20 mRNA and hTERT mRNA in peripheral blood of patients with coloreetal carcinoma was 50. 0% and 56.2% (rdative coefficient: 0.89±0.17 and 0.88±0.17), and9.1% and 0% in benign colorectal lesion, (relative coefficient: 0.11 and 0). CK20 mRNA and hTERT mRNA were notdetected in peripheral blood of healthy subjects. Significant differences were found between colorectal carcinoma patients, benign colorectal lesion patients and healthy subjects (P＜0.05, all). The positive expression rates and relative coefficients of CK20 mRNA and hTERT mRNA were significantly correlated with clinical stage and distant metastasis (P＜0.05 ). The positive expression rates of CK20 mRNA and hTERT mRNA were not correlated with depth of tumor invasion and lymph node metastasis, while the relative coefficients were correlated with them(P＜ 0.05 ). Patients with positive expression had lower survival rates compared with negative expression patients (P＜0.05). CONCLUSION: CK20 mRNA and hTERT mRNA are positively expressed in peripheral blood of patients with colorectal carcinoma. The two markers can be used to predict the micrometastasis in peripheral blood and to the evaluate prognosis in colorectal carcinoma patients.
NETL
NSTL
万方数据
维普
